NASDAQ:ADVM

Adverum Biotechnologies (ADVM) Stock Forecast, Price & News

$1.50

-0.03 (-1.96%)

(As of 03:00 PM ET)

Compare

Today's Range: $1.49
▼
$1.63
50-Day Range: $1.52
▼
$2.23
52-Week Range: $0.53
▼
$2.34

Volume: 136,979 shs
Average Volume: 413,468 shs
Market Capitalization: $151.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.75

Adverum Biotechnologies MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 138.1% Upside
$3.75 Price Target
Short Interest: Healthy
1.52% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.78
Upright™ Environmental Score
News Sentiment: 0.23
Based on 2 Articles This Week
Insider Trading: Selling Shares
$9,426 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.19) to ($0.94) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

128th out of 971 stocks

Biological Products, Except Diagnostic Industry

14th out of 158 stocks

3.4

Analyst's Opinion

Consensus Rating
Adverum Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.75, Adverum Biotechnologies has a forecasted upside of 138.1% from its current price of $1.58.
Amount of Analyst Coverage
Adverum Biotechnologies has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.52% of the float of Adverum Biotechnologies has been sold short.
Short Interest Ratio / Days to Cover
Adverum Biotechnologies has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Adverum Biotechnologies has recently increased by 20.72%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Adverum Biotechnologies does not currently pay a dividend.
Dividend Growth
Adverum Biotechnologies does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Adverum Biotechnologies has received a 77.25% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases ", "Preclinical research services for mental health", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Adverum Biotechnologies is -0.78.

2.9

News and Social Media Coverage

News Sentiment
Adverum Biotechnologies has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Adverum Biotechnologies this week, compared to 0 articles on an average week.
Search Interest
7 people have searched for ADVM on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.
MarketBeat Follows
5 people have added Adverum Biotechnologies to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adverum Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,426.00 in company stock.
Percentage Held by Insiders
Only 5.30% of the stock of Adverum Biotechnologies is held by insiders.
Percentage Held by Institutions
70.87% of the stock of Adverum Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Adverum Biotechnologies are expected to grow in the coming year, from ($1.19) to ($0.94) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Adverum Biotechnologies is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Adverum Biotechnologies is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Adverum Biotechnologies has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Adverum Biotechnologies (NASDAQ:ADVM) Stock

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

ADVM Price History

30 days | 90 days | 365 days | Advanced Chart

ADVM Stock News Headlines

September 21, 2023 | finance.yahoo.com

Adverum Biotechnologies to Participate in Upcoming Investor Conferences

September 19, 2023 | americanbankingnews.com

Short Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Rises By 5.7%

September 29, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

September 6, 2023 | msn.com

Truist Securities Reiterates Adverum Biotechnologies (ADVM) Buy Recommendation

September 5, 2023 | finance.yahoo.com

Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

August 31, 2023 | msn.com

Adverum Biotechnologies (ADVM) Price Target Increased by 13.33% to 4.34

August 22, 2023 | finanznachrichten.de

Adverum Biotechnologies, Inc.: Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer

August 21, 2023 | finance.yahoo.com

Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer

September 29, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

August 14, 2023 | finance.yahoo.com

Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

August 12, 2023 | msn.com

Chardan Capital Upgrades Adverum Biotechnologies (ADVM)

August 11, 2023 | msn.com

Adverum upgraded at Chardan ahead of key readouts for lead asset

August 2, 2023 | msn.com

Adverum Biotechnologies (ADVM) Price Target Increased by 7.14% to 3.83

June 22, 2023 | benzinga.com

Short Volatility Alert: Adverum Biotechnologies

June 12, 2023 | finance.yahoo.com

Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid

June 2, 2023 | finance.yahoo.com

Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference

May 25, 2023 | finance.yahoo.com

Adverum Biotechnologies Announces New Executive Leadership Roles

May 18, 2023 | technews.tmcnet.com

Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec's Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

May 18, 2023 | finance.yahoo.com

Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform

May 18, 2023 | finance.yahoo.com

Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

May 16, 2023 | markets.businessinsider.com

Adverum Biotechnologies (ADVM) Receives a Hold from RBC Capital

May 11, 2023 | finance.yahoo.com

Adverum Biotechnologies Reports First Quarter 2023 Financial Results

May 10, 2023 | finance.yahoo.com

Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference

May 2, 2023 | tmcnet.com

Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT

May 2, 2023 | finance.yahoo.com

Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Geographic Atrophy Secondary to Dry AMD

April 23, 2023 | finance.yahoo.com

Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec

April 21, 2023 | finance.yahoo.com

After losing 12% in the past year, Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners must be relieved by the recent gain

See More Headlines

Receive ADVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

ADVM Company Calendar

Last Earnings: 8/10/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ADVM
CUSIP: N/A
CIK: 1501756
Web: www.adverum.com
Phone: (650) 656-9323
Fax: 650-329-8151
Employees: 123
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.75
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +151.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.33)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-154,540,000.00
Net Margins: N/A
Pretax Margin: -3,704.42%
Return on Equity: -78.63%
Return on Assets: -46.10%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.31
Quick Ratio: 3.31

Sales & Book Value

Annual Sales: $7.50 million
Price / Sales: 20.06
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.82 per share
Price / Book: 0.82

Miscellaneous

Outstanding Shares: 100,990,000
Free Float: 95,640,000
Market Cap: $150.49 million
Optionable: Optionable
Beta: 0.82

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Laurent Fischer (Age 59)
Pres, CEO & Director
Comp: $977.23k

Ms. Linda M. Rubinstein M.A. (Age 56)
CFO, Principal Financial Officer & Principal Accounting Officer
Comp: $111.89k

Mr. Kishor Peter Soparkar J.D. (Age 52)
Chief Operating Officer
Comp: $656.96k

Mr. John W. Rakow J.D. (Age 66)
Sr. VP & Gen. Counsel
Comp: $954.24k

Dr. Setareh Seyedkazemi Pharm.D. (Age 49)
Chief Devel. Officer
Comp: $834.57k

Dr. R. Andrew Ramelmeier Ph.D. (Age 61)
Chief Technology Officer

Dr. Brigit Riley Ph.D. (Age 45)
Chief Scientific Officer

Ms. Dena House
Sr. VP of HR, Organizational Devel. & Learning

Ms. Carla Fiankan
Sr. VP of Regulatory Affairs

Dr. Jim Wang Ph.D.
Chief Regulatory Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ADVM Stock - Frequently Asked Questions

Should I buy or sell Adverum Biotechnologies stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ADVM shares.
View ADVM analyst ratings or view top-rated stocks.
What is Adverum Biotechnologies' stock price forecast for 2023?: 4 brokerages have issued 1 year target prices for Adverum Biotechnologies' shares. Their ADVM share price forecasts range from $2.00 to $6.00. On average, they anticipate the company's stock price to reach $3.75 in the next year. This suggests a possible upside of 151.7% from the stock's current price.
View analysts price targets for ADVM or view top-rated stocks among Wall Street analysts.
How have ADVM shares performed in 2023?: Adverum Biotechnologies' stock was trading at $0.5795 at the beginning of the year. Since then, ADVM shares have increased by 157.1% and is now trading at $1.4901.
View the best growth stocks for 2023 here.
Are investors shorting Adverum Biotechnologies?: Adverum Biotechnologies saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 1,340,000 shares, an increase of 20.7% from the August 31st total of 1,110,000 shares. Based on an average daily trading volume, of 438,300 shares, the days-to-cover ratio is currently 3.1 days. Currently, 1.5% of the shares of the company are short sold.
View Adverum Biotechnologies' Short Interest.
When is Adverum Biotechnologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our ADVM earnings forecast.
How were Adverum Biotechnologies' earnings last quarter?: Adverum Biotechnologies, Inc. (NASDAQ:ADVM) announced its earnings results on Thursday, August, 10th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.01.

What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO?: 3 employees have rated Adverum Biotechnologies Chief Executive Officer Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among the company's employees.
What other stocks do shareholders of Adverum Biotechnologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA).
What is Adverum Biotechnologies' stock symbol?: Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."
How do I buy shares of Adverum Biotechnologies?: Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Adverum Biotechnologies' stock price today?: One share of ADVM stock can currently be purchased for approximately $1.49.
How much money does Adverum Biotechnologies make?: Adverum Biotechnologies (NASDAQ:ADVM) has a market capitalization of $150.49 million and generates $7.50 million in revenue each year. The biotechnology company earns $-154,540,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.
How many employees does Adverum Biotechnologies have?: The company employs 123 workers across the globe.
How can I contact Adverum Biotechnologies?: Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The official website for the company is www.adverum.com. The biotechnology company can be reached via phone at (650) 656-9323, via email at mlacy@adverum.com, or via fax at 650-329-8151.

This page (NASDAQ:ADVM) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial